J Urol 2001;165:441–444. OS is the primary endpoint. No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer. Boyle HJ, Jouanneau E, Droz JP, . For patients with intermediate-risk disease, the cure rate is approximately 70% with the standard chemotherapy regimen of 4 cycles of BEP.100,101 Therefore, the NCCN Panel recommends 4 cycles of BEP (preferred), or 4 cycles of etoposide, ifosfamide, and cisplatin (VIP)100,102 for patients who may not tolerate bleomycin, for the treatment of intermediate-risk (stage IIIB) nonseminoma. J Clin Oncol 2000;18:1725–1732. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma. Science 2017;357:409–413. For patients with no residual mass or a residual mass <1 cm, surveillance is recommended. Testicular ultrasound serves to confirm the presence of a testicular mass, determine whether a mass is intra- or extratesticular, and to explore the contralateral testis.22 Testicular GCTs are typically heterogeneous, hypoechoic, and vascular on ultrasound. Stephenson AJ, Bosl GJ, Motzer RJ, . However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Kondagunta GV, Bacik J, Bajorin D, . Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors. Elevated levels of beta-hCG, LDH, or AFP should be followed up with repeated tests to allow precise staging. Sweeney CJ, Hermans BP, Heilman DK, . High-dose chemotherapy is the preferred third-line option if it has not been previously received (see TEST-G, page 1547). Brydøy M, Fosså SD, Klepp O, . In patients with clinical stage I seminoma, the National Comprehensive Cancer Network (NCCN) recommends surveillance with history and physical examination (H&P) and abdominal and pelvic computed tomography (CT). Staging of testicular GCTs is based on determination of the extent of disease and assessment of postorchiectomy levels of serum tumor markers.12 The tumor (T), node (N), and metastasis (M) staging system used by the AJCC is the internationally accepted standard for cancer staging and is a major factor influencing prognosis and treatment decisions. For patients with a partial response to second-line therapy (as indicated by residual masses on CT scan) and normal marker levels, surgical resection of all residual masses is recommended followed by surveillance. Eur Urol 2011;59:556–562. Sheinfeld J, Motzer RJ, Rabbani F, . For patients with stage IIA disease with persistently elevated AFP and/or beta-hCG levels, the NCCN Panel recommends primary chemotherapy with 3 cycles of BEP or 4 cycles of EP (both category 1; both preferred).60,86 A bleomycin-free regimen should be considered in patients with reduced or borderline glomerular filtration rate (GFR), in patients over the age of 50, and in patients with chronic obstructive pulmonary disease or other lung disease resulting in reduced pulmonary function. Cancer Epidemiol Biomarkers Prev 2010;19:1151–1159. Daneshmand S, Albers P, Fosså SD, . Am J Clin Oncol 2015;38:373–376. Endocr Relat Cancer 2010;17:R109–R121. Instead, the NCCN Guidelines recommend managing patients with stage I nonseminoma based on the presence or absence of lymphovascular invasion (LVI), invasion of the spermatic cord, or invasion of the scrotum, which are factors known to be associated with an increased risk of relapse.35–43. The IGCCCG good-risk group includes patients with stages IS, IIA (S1), IIB (S1), IIC, and IIIA disease (see TEST-11, page 1536). Kurobe M, Kawai K, Oikawa T, . For example, stage I transformed teratoma is preferentially managed with retroperitoneal lymph node dissection (RPLND) whereas other stage I nonseminomas are typically managed using surveillance. If embryonal, yolk sac, choriocarcinoma, or seminoma elements are found in the residual mass, then 2 cycles of chemotherapy with EP; paclitaxel, ifosfamide, and cisplatin (TIP); VIP; or vinblastine, ifosfamide, and cisplatin (VelP) should be administered. 2017. Kollmannsberger C, Nichols C, Bamberg M, . All rights reserved. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. Onkologie 2011;34:416–420. Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. Asian J Androl 2013;15:558–563. J Clin Oncol 2010;28:1706–1713. Beyer J, Albers P, Altena R, . Sturgeon JF, Moore MJ, Kakiashvili DM, . Defining a new prognostic index for stage I nonseminomatous germ cell tumors using CXCL12 expression and proportion of embryonal carcinoma, Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review, Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort, Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis, Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse, Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma--predominant testis cancer, Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Therefore, patients who choose surveillance should adhere to the follow-up schedule. Culine S, Kerbrat P, Kramar A, . Ann Oncol 2004;15:493–497. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. Stage II and stage III disease treated with systemic chemotherapy should be followed by surgical resection of any residual masses. Spermatic cord contamination in testicular cancer. Patients with elevated but stable tumor marker levels should be closely surveilled. Therefore, patients should not be treated with chemotherapy for systemic disease if the only evidence of systemic disease is an elevation of LDH. Although no single follow-up plan is applicable to all patients, the NCCN Panel has provided guidance for the follow-up of patients with nonseminoma for the first 5 years after the completion of therapy. Turk J Urol 2013;39:249–252. N Engl J Med 2015;372:2509–2520. J Clin Oncol 2011;29:2178–2184. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options-an analysis from the global germ cell cancer group. Calaway AC, Einhorn LH, Masterson TA, . Additionally, patients with postorchiectomy beta-hCG levels >5,000 IU/L should undergo brain MRI because they are at an increased risk of having brain metastases. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Robinson R, Tait CD, Clarke NW, . Feldman DR, Sheinfeld J, Bajorin DF, . The long-term follow-up schedule for stage IIB nonseminoma patients is similar to the follow-up schedule outlined previously for patients with stage IIA nonseminoma and is dependent on the primary treatment modality and postsurgical management received by the patient (see “Follow-up for Nonseminoma Stage IIA,” page 1541, and TEST-B, pages 1541–1543). High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. Ann Oncol 2000;11:553–559. Ann Oncol 2013;24:878–888. 29 June 2017: New eUpdate featuring Updated Treatment Recommendations and Tables for Testicular Seminoma and Non-Seminoma. Available at: https://seer.cancer.gov/statfacts/html/testis.html. The MRI protocol should include visualization of the retroperitoneal and pelvic nodes and should be performed in centers with experience in interpreting MRI results for testicular cancer. Subsequent management after primary chemotherapy depends on the size of the residual mass on CT scan (see TEST-9, page 1534). This means that one or both testicles fail to move from the abdomen (belly) into the scrotum before birth. For each guideline, we documented the cancer type (solid tumor or hematologic malignancy), version, and date of publication. J Clin Oncol 2004;22:464–467. Kim W, Rosen MA, Langer JE, . American Cancer Society guideline for diet and physical activity for cancer prevention. N Engl J Med 2007;357:340–348. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Eur J Cancer 2017;87:140–146. The rationale for this extended region of dissection is the greater likelihood of bilateral disease with greater tumor burden.91 Referral to high-volume centers should be considered for surgical resection of masses postchemotherapy. Nichols CR, Catalano PJ, Crawford ED, . Huddart RA, Reid AM. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care–registry data from an outcomes research project of the German Testicular Cancer Study Group. Turnbull C, Rahman N. Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. Legal Notices| In a recent retrospective study, a total of 76 relapses were detected among 561 patients with stage I nonseminoma managed using active surveillance after orchiectomy.66 All relapses were detected with either rising serum tumor markers or abnormal routine follow-up CT scans; not a single relapse was detected using chest X-ray alone. The management of patients with stage IIB nonseminoma after primary treatment with either nerve-sparing RPLND or chemotherapy is similar to the postprimary management scheme outlined previously for patients with stage IIA nonseminoma (see “Management of Nonseminoma Stage IIA After Primary Treatment,” page 1541). Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma: clinical outcomes and prognostic factors for relapse in a large US cohort. van Dijk MR, Steyerberg EW, Habbema JD. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. If the inline PDF is not rendering correctly, you can download the PDF file here. Patients who have an incomplete response to chemotherapy require more frequent imaging than is outlined in the table. Ann Oncol 2004;15:1377–1399. Shanmugalingam T, Soultati A, Chowdhury S, . 2019. Zuniga A, Kakiashvili D, Jewett MA. Since 2008, the Testicular Cancer Guidelines contains a separate chapter on testicular stromal tumours. Clin Epidemiol 2013;5:417–427. The panel prefers that patients with recurrent nonseminoma be treated at centers with expertise in the management of this disease. Oliver RT, Ong J, Shamash J, . Teratomas are sometimes classified as either mature or immature, but this distinction is of no known significance in adult men and does not affect management in these patients. Serum tumor marker assays are optional. J Urol 2000;163:796–801. The major morbidity associated with bilateral RPLND is retrograde ejaculation, resulting in infertility. Culine S, Kramar A, Théodore C, . Oncol Rep 1998;5:1425–1429. An ongoing, randomized, international phase III trial (TIGER) will compare second-line conventional-dose chemotherapy with high-dose chemotherapy in patients with relapsed GCTs.118 The foundation of the TIGER trial was formed based on the results of a large retrospective analysis by Lorch et al119 which showed the superiority of carboplatin-based high-dose chemotherapy compared with cisplatin-based conventional-dose chemotherapy with respect to 2-year progression-free survival (50% vs 28%; PP120 The TIGER trial will randomize patients with unequivocal disease progression after cisplatin-based primary chemotherapy to receive conventional-dose TIP or high-dose paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide with stem cell support. A trial of antibiotics is never warranted in a man with a mass suspicious for GCT but can be considered in men with pain without a mass on further workup. Clinical trial enrollment is also an option for patients with unresectable late relapse. Adv Urol 2018;2018:7272541. Raphael MJ, Wei X, Karim S, . Eur Urol 2000;37:582–594. Ann Oncol 2008;19:1619–1623. Study Measures. Elevated levels of serum beta-hCG, LDH, or AFP should be followed up with repeated tests. Cancer statistics, 2019. 2017. Olofsson SE, Tandstad T, Jerkeman M, et al. At the beginning of each NCCN Guidelines Panel meeting, panelmembers reviewall potential conflicts of interest.NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself. Kondagunta GV, Bacik J, Donadio A, . Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Ann Oncol 2007;18:917–924. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. These NCCN Guidelines® are currently available as Version 1.2019. The 4 types of nonseminomas are embryonal carcinoma, choriocarcinoma, yolk sac tumor, and teratoma.11 Most nonseminomas are mixed tumors of these 4 subtypes. Jones RH, Vasey PA. Part I: testicular cancer--management of early disease. Lancet Oncol 2003;4:730–737. Pishgar F, Haj-Mirzaian A, Ebrahimi H, . BJU Int 2016;117:249–252. Horwich A, Norman A, Fisher C, . J Cancer Res Clin Oncol 2015;141:127–133. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. Ann Oncol 2013;24:508–513. Neurotoxicity among survivors of testicular cancer: a population-based study. J Clin Oncol 2001;19:2020–2025. Nonseminomatous GCTs include nonseminoma tumors, mixed seminoma/nonseminoma tumors, and seminoma tumors in patients with elevated serum AFP levels. This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer focuses on the diagnosis and management of nonseminomatous GCTs (to view the complete and most recent version of these guidelines, visit NCCN.org). Additionally, heterophile antibodies have been reported to result in substantially elevated false-positive beta-hCG results (>400 IU/L), so clinicians should consider repeating the test using a different assay if a false-positive result is suspected due to the absence of radiographic evidence of disease.17,18. Miller JC, Einhorn LH. We would like to show you a description here but the site won’t allow us. Prognosis for patients with brain metastases remains poor, with a lack of evidence from prospective trials to guide treatment decisions. The AJCC TNM staging system incorporates serum tumor marker elevation as a distinct category (S), which is unique to this organ site. Clin Chem 2018;64:270–278. Vasdev N, Moon A, Thorpe AC. Sperm banking and rate of assisted reproduction treatment: insights from a 15-year cryopreservation program for male cancer patients. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. The management of patients with stage IS nonseminoma after primary treatment with chemotherapy is described subsequently (see “Management of Good, Intermediate, and Poor-Risk Nonseminoma After Chemotherapy,” page 1544). Referral to high-volume centers should be considered for surgical resection of residual masses after chemotherapy. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs. The frequency of these tests varies with the primary treatment modality received by the patient (see Tables 6 and 7, pages 1541 and 1542, respectively). Treatment of good-risk disease is designed to limit toxicity while maintaining maximal efficacy. to save searches and organize your favorite content. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. J Natl Cancer Inst 2005;97:1056–1066. Patients with elevated but stable marker levels should be closely surveilled. Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis. Chest X-ray may be used for routine follow-up, but chest CT with contrast is preferred in patients with thoracic symptoms. The recommendations regarding the uses and indications in the NCCN Compendium have been derived directly from the NCCN Guidelines. World J Urol 2004;22:47–54. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indiana University experience. Often, patients will present with testicular discomfort or swelling suggestive of epididymitis or orchitis. Beta-hCG is the most commonly elevated serum tumor marker in testicular cancer. The long-term follow-up for patients with stage I nonseminoma without risk factors includes history and physical examination, serum tumor marker assessment, abdominal/pelvic CT scan, and chest X-ray. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. Patients with clinical stage I pure teratoma and normal markers should receive either surveillance or RPLND. NCCN clinical practice guidelines in oncology: testicular cancer J Natl Compr Canc Netw. Nonomura N, Nishimura K, Takaha N, . J Urol 2003;170:1159–1162. The frequency of these tests varies with the primary treatment modality and postsurgical management received by the patient (see Tables 8, 9, and 10 on TEST-B, pages 1542 and 1543). Morris MJ, Bosl GJ. Although it is rare, when a patient presents with: 1) markedly elevated beta-hCG or AFP levels; 2) a testicular mass and/or disease distribution typical for a testicular, retroperitoneal, or mediastinal GCT; or 3) a clinical scenario in which, due to the bulk, signs, or symptoms of disease, the risk of delaying systemic therapy outweighs the benefit of a tissue diagnosis, chemotherapy may be started immediately without waiting for a biopsy diagnosis or performing orchiectomy. If there is a partial radiographic response to chemotherapy (as indicated by the presence of residual masses) and tumor marker levels are normal, then surgical resection of all residual masses is recommended (see TEST-12, page 1537).105–108 As previously stated, referral to high-volume centers should be considered for surgical resection of masses postchemotherapy. Ann Oncol 2015;26:1396–1401. Generally, decisions to treat should not be based solely on AFP values <20 ng/mL. Trojan A, Joller-Jemelka H, Stahel RA, . If the ultrasound findings show a mass concerning for malignancy, then an inguinal orchiectomy is generally performed to make a diagnosis. Lancet Oncol 2003;4:738–747. False-positive serum human chorionic gonadotropin (HCG) in a male patient with a malignant germ cell tumor of the testis: a case report and review of the literature. AJCC Cancer Staging Manual, 8th Ed. Pembrolizumab, an anti-PD-1 antibody, was approved by the FDA for the treatment of patients with unresectable or metastatic MSI-H/dMMR solid tumors that have progressed after previous treatment and who have no satisfactory alternative treatment options.129 This first-ever tissue- and site-agnostic indication was based on data from phase II clinical trials that demonstrated the efficacy of pembrolizumab in MSI-H/dMMR solid tumors.130,131 In the only trial (phase II) investigating the efficacy of immunotherapy in testicular cancer, 12 patients with nonseminoma GCTs that progressed after first-line cisplatin-based chemotherapy and at least 1 salvage regimen (high-dose or conventional-dose chemotherapy) were treated with pembrolizumab.132 Two patients experienced stable disease for 28 and 19 weeks, respectively, but no partial or complete responses were seen. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. Updates in Version 1.2019 of the NCCN Guidelines for Testicular Cancer from Version 2.2018 include: Global Changes • The NCCN Categories of Preference have been applied to all of the suggested treatment regimens. The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Updates in Version 2.2016 of the NCCN Guidelines for Testicular Cancer from Version 1.2016 include: TEST-5 • Post-chemotherapy, for no residual mass or residual mass ≤3 cm and normal markers, the follow-up was redirected to Table 3 on J Clin Oncol 2005;23:6549–6555. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. The significance of spermatic cord involvement by testicular germ cell tumors: should we be staging discontinuous invasion from involved lymphovascular spaces differently from direct extension? The study showed 6 grade-3 adverse events, but no immune-related adverse events were reported. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. High-dose chemotherapy has been added as a validated treatment option. Similarly, further workup should be considered before initiating treatment of mildly elevated beta-hCG (generally <20 IU/L). Oncology 2013;85:21–26. Ragni G, Somigliana E, Restelli L, . International trends in the incidence of testicular cancer, 1973-2002. Testicular GCTs are sensitive to platinum-based chemotherapy, and patients have high cure rates even with metastatic disease. International Germ Cell Cancer Collaborative Group. Behnia M, Foster R, Einhorn LH, . J Clin Oncol 2005;23:9290–9294. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 17(1, Suppl 2)36–39. Treatment options for clinical stage I disease after inguinal orchiectomy include surveillance, systemic therapy, and RPLND. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Testicular Cancer outline the diagnosis, workup, risk assessment, treatment, and follow-up schedules for patients with both pure seminoma and nonseminoma. Primary treatment of patients with stage IIB nonseminoma depends on postorchiectomy tumor marker levels and radiographic findings (see TEST-8, page 1533). NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®), and the NCCN Radiation Therapy Compendium™ for Testicular Cancer. Surgical management of low-stage nonseminomatous germ cell testicular cancer. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. National Cancer Institute, Bethesda, MD. Eur J Cancer 2001;37:576–582. Surveillance is also a recommended primary treatment option for patients with stage I nonseminoma with risk factors. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. NCCN Academy for Excellence & Leadership in Oncology™: NCCN Virtual Annual Congress: Hematologic Malignancies™, NCCN Global Academy for Excellence & Leadership in Oncology™, Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care, Mycosis Fungoides and Sezary Syndrome, April 27, New NCCN Guidelines for Pediatric Cancers: A Webinar Series, Patient Webinars - Know What Your Doctors Know, NCCN Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™, Delivering Value for Patients Across the Oncology Ecosystem, Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care, The State of Cancer Care in America: Impact of State Policy on Access to High-Quality Cancer Care, Policy Challenges and Opportunities to Address Changing Paradigms in Cancer Care Delivery, Policy Strategies for the “New Normal” in Health care to Ensure Access to High Quality Cancer Care, NCCN Compendia, NCCN Templates, and NCCN Flash Updates, NCCN Compendium, NCCN Templates, and NCCN Flash Updates, NCCN Pharmacy Directors Forum White Paper: Operationalizing the Safe and Efficient Use of Biosimilars, NCCN Health Information Technology Licensees, NCCN Insights: Analytics, Research & Consulting, NCCN Collaboration with the National Business Group on Health, Points to Consider on the Best Practices for Biorepositories, Registries and Databases, Get Involved - Opportunities for Global Collaboration and Sponsorship, Clinical Trials at NCCN Member Institutions, Find ORP Funded Clinical Trials at NCCN Member Institutions. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. When patients with a histologically “pure” seminoma have an elevated level of AFP, it is generally interpreted as meaning the tumor is a mixed GCT and that undetected nonseminomatous elements are present in addition to the seminoma.13,19–21 However, a small number of people have a chronically elevated serum AFP level, and clinicians should be cautious about starting treatment for a mildly elevated but stable AFP level. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. If tumor marker levels are elevated and persistently rising, the panel recommends third-line therapy (see TEST-G, previous page and above, and “Third-Line Therapy,” subsequent section). Patients with mildly elevated and normalizing markers should be considered for surgical resection of residual masses followed by surveillance. J Clin Oncol 2007;25:5597–5602. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tuto Piano Christophe, Kyrie 6 Asia On Feet, Challeat Legion D'honneur, Bass Tab Reggae, Le Grand Môme Mots Fléchés, Purple Rain Guitar Lesson Acoustic, Nous Sommes Tous Des Féministes Livre, Films 2021 Wikipedia, Prénom Sarah Interdit Au Maroc, Swan Lake Piano Sheet Music Easy, Voyage Voyage Soap And Skin Chords,